Time to first passage of meconium and defecation frequency preceding necrotizing enterocolitis in preterm infants: a case-control study.

"Declarations Ethical approvalThis study was performed in line with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the local institutional review board of Amsterdam UMC, location VUmc, Amsterdam, the Netherlands (approval number A2020.190). Consent to participateWritten informed consent was obtained from both parents and/or legal guardians of all infants. Competing interestsN.K.H. de Boer has served as a speaker for AbbVie and MSD and has served as consultant and/or principal investigator for TEVA Pharma BV and Takeda; he has received a (unrestricted) research grant from Falk, TEVA Pharma BV, MLDS and Takeda. All outside the submitted work. I.J.N. Koppen has served as a speaker for Wellspect and as a consultant for Mahana Therapeutics. All outside the submitted work. M.A. Benninga has served as a speaker for Abbott, Menarini and United Pharmaceuticals and has served as consultant and/or principal investigator for Coloplast, Wellspect, Norgine, Allergan, Mallinckrodt, Takeda, FrieslandCampina, Danone, HIPP, United Pharmaceuticals. All outside the submitted work. W.J. de Jonge holds unrestricted research grants: GlaxoSmithKline, Galvani Bioelectronics, Mead Johnson Nutrition, Reckitt Bengiser, Alimentiv BV, MRM health, Bristol Myers Squibb, Friesland Campina, Horaizon BV, GenDX B,and received honoraria from: Alimentiv, Janssen-Cilag BV, ESMN, AGA, Mead Johnsson Nutrition, as well as co-founder and grant support: DSCN Research BV, Amsterdam,: AIBiomics BV; and shareholder of: Amstel Biotech BV. Competing interests N.K.H. de Boer has served as a speaker for AbbVie and MSD and has served as consultant and/or principal investigator for TEVA Pharma BV and Takeda; he has received a (unrestricted) research grant from Falk, TEVA Pharma BV, MLDS and Takeda. All outside the submitted work. I.J.N. Koppen has served as a speaker for Wellspect and as a consultant for Mahana Therapeutics. All outside the submitted work. M.A. Benninga has served as a speaker for Abbott, Menarini and United Pharmaceuticals and has served as consultant and/or principal investigator for Coloplast, Wellspect, Norgine, Allergan, Mallinckrodt, Takeda, FrieslandCampina, Danone, HIPP, United Pharmaceuticals. All outside the submitted work. W.J. de Jonge holds unrestricted research grants: GlaxoSmithKline, Galvani Bioelectronics, Mead Johnson Nutrition, Reckitt Bengiser, Alimentiv BV, MRM health, Bristol Myers Squibb, Friesland Campina, Horaizon BV, GenDX B,and received honoraria from: Alimentiv, Janssen-Cilag BV, ESMN, AGA, Mead Johnsson Nutrition, as well as co-founder and grant support: DSCN Research BV, Amsterdam,: AIBiomics BV; and shareholder of: Amstel Biotech BV."

"Funding sources This research received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 814168."